Kiniksa Pharmaceuticals International, plc - Class A Ordinary Shares (KNSA)

Profit growth is outpacing revenue gains, giving the company firepower to advance pipeline candidates without diluting shareholders.

ARCALYST revenue surged 58% year-over-year as the company raised full-year guidance.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) raised its full-year 2026 revenue guidance after reporting third-quarter ARCALYST revenue growth of 58% year over year, as the company continued to expand use of the drug for recurrent pericarditis and advance its clinical pipeline. The company no

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) said its commercialized recurrent pericarditis treatment ARCALYST continues to grow, while the company has begun a pivotal Phase 3 study of follow-on candidate KPL-387. Speaking at a Canaccord Genuity event, Chief Operating Officer Ross Moat said

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) reported second-quarter ARCALYST revenue of $243.6 million, up 55% from a year earlier and more than $29 million from the first quarter, as the company cited continued expansion in both new and repeat prescribers for the recurrent pericarditis trea

Kiniksa (KNSA) Q1 2026 Earnings Transcript